Back to discover
Disease

Haemophilus Infections

Late-stage therapeutic developmentEmerging research
MeSHHaemophilus Infections
1
Publications
5
Clinical trials
2019
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

3 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
5
All trials
0
Active
5
Late-stage
5
Completed
Late-stage studies

A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem® DTwP-HepB-Hib) in Uniject™ With Quinvaxem® Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age

Phase 3 · Completed · Crucell Holland BV

An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age

Phase 3 · Completed · Merck Sharp & Dohme LLC

A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age

Phase 4 · Completed · Crucell Holland BV

Immunogenicity and Safety of Pentaxim in South African Infants

Phase 3 · Completed · Sanofi

Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand

Phase 4 · Completed · Sanofi
Recently completed

A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem® DTwP-HepB-Hib) in Uniject™ With Quinvaxem® Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age

Phase 3 · Completed · Crucell Holland BV

A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age

Phase 4 · Completed · Crucell Holland BV

Immunogenicity and Safety of Pentaxim in South African Infants

Phase 3 · Completed · Sanofi

An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age

Phase 3 · Completed · Merck Sharp & Dohme LLC

Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand

Phase 4 · Completed · Sanofi

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Leading journals1
  • American journal of respiratory and critical care medicine1
Leading researchers8
  • Anzueto A1
  • Brozek J1
  • Cooley LA1
  • Crothers K1
  • Dean NC1
  • Fine MJ1
  • Flanders SA1
  • Griffin MR1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infections with bacteria of the genus HAEMOPHILUS.

Identifiers
MeSHHaemophilus Infections
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.